Literature DB >> 421302

Echocardiographic assessment of cardiac anatomy and function in hypertensive subjects.

D D Savage, J I Drayer, W L Henry, E C Mathews, J H Ware, J M Gardin, E R Cohen, S E Epstein, J H Laragh.   

Abstract

Cardiovascular complications are a major source of morbidity and mortality in hypertensive patients. To assess the prevalence of anatomic and functional abnormalities of the heart in such patients, we studied 234 asymptomatic subjects with mild-to-moderate systemic hypertension by echocardiography. After adjusting the echocardiographic values for age and body surface area, we found abnormally increased ventricular septal and/or posterobasal free-wall thickness in 61% of the hypertensive subjects. We found increased left atrial, aortic root, and left ventricular internal dimension (at end-diastole) in 5-7%, and decreased mitral valve closing velocity (E-F slope) and left ventricular ejection fraction were noted in six and 15% of the subjects, respectively. Four percent of the patients had disproportionate septal thickening (i.e., ventricular septal-to-left ventricular free-wall thickness ratio greater than or equal to 1.3). In contrast to the high prevalence of cardiac abnormalities detected by echocardiography, less than 10% of the hypertensive subjects had abnormal 12-lead ECGs or abnormal chest x-rays. These findings demonstrate a high prevalence of cardiac abnormalities in a population of asymptomatic hypertensive subjects. These abnormalities can be detected by echocardiography before they are otherwise apparent.

Entities:  

Mesh:

Year:  1979        PMID: 421302     DOI: 10.1161/01.cir.59.4.623

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  31 in total

Review 1.  Diabetic nephropathy. Its relationship to hypertension and means of pharmacological intervention.

Authors:  T Baba; S Neugebauer; T Watanabe
Journal:  Drugs       Date:  1997-08       Impact factor: 9.546

2.  Left ventricular hypertrophy and diastolic functional abnormalities in black and white hypertensive patients.

Authors:  D D Savage
Journal:  J Natl Med Assoc       Date:  1987-03       Impact factor: 1.798

3.  Clinical and coronary arteriographic profile of 100 black Americans: focus on subgroup with undiagnosed suspicious chest discomfort.

Authors:  P Carryon; M M Matthews
Journal:  J Natl Med Assoc       Date:  1987-03       Impact factor: 1.798

4.  End organ changes associated with the self-regulatory treatment of mild essential hypertension?

Authors:  G C McCoy; S Fein; E B Blanchard; D A Wittrock; R J McCaffrey; L Pangburn
Journal:  Biofeedback Self Regul       Date:  1988-03

5.  Left ventricular hypertrophy.

Authors:  J Chambers
Journal:  BMJ       Date:  1995-07-29

6.  Asymmetric septal hypertrophy and hypertrophic cardiomyopathy.

Authors:  R Emanuel; J Marcomichelakis; R Withers; K O'Brien
Journal:  Br Heart J       Date:  1983-04

7.  Recent pathogenic aspects in essential hypertension and hypertension associated with diabetes mellitus.

Authors:  P Weidmann
Journal:  Klin Wochenschr       Date:  1980-10-01

8.  Utilizing ECG-Based Heartbeat Classification for Hypertrophic Cardiomyopathy Identification.

Authors:  Quazi Abidur Rahman; Larisa G Tereshchenko; Matthew Kongkatong; Theodore Abraham; M Roselle Abraham; Hagit Shatkay
Journal:  IEEE Trans Nanobioscience       Date:  2015-04-24       Impact factor: 2.935

9.  Association of the beta-1 adrenergic receptor carboxyl terminal variants with left ventricular hypertrophy among diabetic and non-diabetic survivors of acute myocardial infarction.

Authors:  Anna E Hakalahti; Jari M Tapanainen; Juhani M Junttila; Kari S Kaikkonen; Heikki V Huikuri; Ulla E Petäjä-Repo
Journal:  Cardiovasc Diabetol       Date:  2010-08-23       Impact factor: 9.951

10.  Specificity of systolic anterior motion of anterior mitral leaflet for hypertrophic cardiomyopathy. Prevalence in large population of patients with other cardiac diseases.

Authors:  B J Maron; J S Gottdiener; L W Perry
Journal:  Br Heart J       Date:  1981-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.